Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01)
Funds work on how GLP-1 and related drugs change cancer risk — raising it for some cancers, lowering it for others.
Incretin mimetics — GLP-1 agonists, GIP-1 agents, and dual GLP-1/GIP-1 drugs — are now taken by very large numbers of people, and the evidence so far suggests they may raise the risk of some obesity-related cancers while lowering the risk of others. Nobody knows why.
This notice funds preclinical and patient-based studies of the mechanisms behind that. NIH is explicit about a second goal alongsid…
Preclinical and patient-based studies of the mechanisms by which incretin mimetics — GLP-1 agonists or antagonists, GIP-1 agents, and dual GLP-1/GIP-1 agents — affect cancer risk, rather than shorter-term outcomes such as weight loss and diabetes.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up